{"id":872028,"date":"2025-08-06T18:41:21","date_gmt":"2025-08-06T22:41:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-to-exclusively-prioritize-the-clinical-advancement-of-ker-065\/"},"modified":"2025-08-06T18:41:21","modified_gmt":"2025-08-06T22:41:21","slug":"keros-to-exclusively-prioritize-the-clinical-advancement-of-ker-065","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-to-exclusively-prioritize-the-clinical-advancement-of-ker-065\/","title":{"rendered":"Keros to Exclusively Prioritize the Clinical Advancement of KER-065"},"content":{"rendered":"
\n

\n Company Discontinuing Development of Cibotercept (KER-012)<\/em>\n <\/p>\n

\n Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure <\/em>
\n
\n and Strategic Realignment <\/em>\n <\/p>\n

LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (\u201cKeros\u201d) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (\u201cTGF-\u00df\u201d) family of proteins, today announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065.<\/p>\n

As part of this initiative, the Company will discontinue all material, internal development activities related to cibotercept. This decision comes after the termination of the development of cibotercept in pulmonary arterial hypertension (\u201cPAH\u201d), following the analysis of all available safety and efficacy data from the TROPOS Phase 2 clinical trial in patients with PAH, which was previously announced on May 29, 2025.<\/p>\n

Keros also today announced several Board of Directors (the \u201cBoard\u201d) and leadership transitions intended to support the Company\u2019s streamlined vision and operational focus. These actions reflect Keros\u2019 confidence in the therapeutic potential of KER-065 and will better enable the Company to achieve its mission of delivering meaningful and potentially disease-modifying benefits to patients.<\/p>\n

\u201cIn line with Keros\u2019 commitment to delivering value for stockholders and patients, we have made the decision to streamline our operations and focus exclusively on advancing KER-065, an asset we believe has therapeutic potential for individuals living with Duchenne muscular dystrophy (\u201cDMD\u201d),\u201d said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros Therapeutics. \u201cBy prioritizing our most promising clinical program, we expect Keros to operate with greater precision and urgency to unlock additional value for stockholders. With a refined strategy, streamlined leadership and a strong clinical foundation, we believe we are well-positioned to initiate the next phase of clinical development for KER-065.\u201d<\/p>\n

The Company previously announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers, with the trial achieving key objectives for safety, tolerability, pharmacokinetics and pharmacodynamics. The Company believes that the robust data supports the advancement of the program into a Phase 2 clinical trial of KER-065 in patients with DMD, which the Company expects to initiate in the first quarter of 2026, subject to positive regulatory interaction.<\/p>\n

\n
\n Board and Leadership Changes <\/em>
\n <\/strong>\n <\/p>\n

To support Keros\u2019 strategic realignment,\u00a0the Company is undergoing the following Board and leadership transitions:<\/p>\n